Session » (2504–2523) Vasculitis – ANCA-Associated Poster III
- 10:30AM-12:30PM
-
Abstract Number: 2519
A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan
- 10:30AM-12:30PM
-
Abstract Number: 2505
Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2513
Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg
- 10:30AM-12:30PM
-
Abstract Number: 2522
Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study
- 10:30AM-12:30PM
-
Abstract Number: 2514
Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database
- 10:30AM-12:30PM
-
Abstract Number: 2512
Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2521
DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2520
Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2510
Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.
- 10:30AM-12:30PM
-
Abstract Number: 2518
Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study
- 10:30AM-12:30PM
-
Abstract Number: 2516
Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
- 10:30AM-12:30PM
-
Abstract Number: 2508
Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort
- 10:30AM-12:30PM
-
Abstract Number: 2509
Predicting future relapse with proteomics in ANCA-Associated Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2517
Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2523
Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)
- 10:30AM-12:30PM
-
Abstract Number: 2507
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
- 10:30AM-12:30PM
-
Abstract Number: 2515
The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2511
The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 2506
Timing, Management, and Outcomes of Venous Thromboembolic Events in ANCA-Associated Vasculitis: A Retrospective Cohort Study